From the Journals

Siponimod trial ‘first’ to show delayed disability in secondary progressive MS


 

FROM THE LANCET

The EXPAND study was funded by Novartis. The lead author Dr. Kappos has received research and educational support funding via his institution from Novartis and multiple other pharmaceutical companies. Editorial author Dr. Metz has received grants from Roche and Biogen and personal fees from EMD Serono. The other editorial author, Dr. Liu, reported receiving personal fees from Novartis and personal fees and grants from EMD Serono. Dr. Liu was a back-up treating neurologist in the EXPAND trial.

SOURCE: Kappos L et al. Lancet. 2018 Mar 22. doi: 10.1016/S0140-6736(18)30475-6, and Metz L and Liu W. Lancet. 2018 Mar 22. doi: 10.1016/S0140-6736(18)30426-4.

Pages

Recommended Reading

VIDEO: New MS ambulatory measure could fill clinical gap
MDedge Internal Medicine
VIDEO: Efficacy of DMTs decreases with age
MDedge Internal Medicine
Switching RRMS patients to daclizumab beta appears safe
MDedge Internal Medicine
Third course of alemtuzumab can improve MS outcomes
MDedge Internal Medicine
VIDEO: Managing the alemtuzumab paradox
MDedge Internal Medicine
Nearly half of MS patients treated by primary docs miss out on meds
MDedge Internal Medicine
Physicians often bypass cognition, depression screening in MS
MDedge Internal Medicine
Study identifies characteristics that may constitute the MS prodrome
MDedge Internal Medicine
MS medication withdrawn because of safety concerns
MDedge Internal Medicine
The case for being open-minded about medical marijuana
MDedge Internal Medicine